Revumenib Citrate Chemical Properties

InChIKey

UBXFWTFPYATLBT-SGBGZXBGNA-N

SMILES

C([C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)N1CCC2(CC1)CN(C1=NC=NC=C1OC1C=CC(=CC=1C(=O)N(CC)C(C)C)F)C2.C(O)(C(=O)O)(CC(=O)O)CC(=O)O.O |&1:1,4,r|

Revumenib Citrate Usage And Synthesis

Description

Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations. Revumenib Citrate is a common salt of Revumenib.